Clinical Indicators That Identify Risk of Deteriorating and Dying in People with a Hematological Malignancy: A Case-Control Study with Multivariable Analysis.

J Palliat Med 2018 12 17;21(12):1729-1740. Epub 2018 Oct 17.

4 Haematology and Bone Marrow Transplant Unit, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Herston, Australia.

Background: Identifying people who are at risk of deteriorating and dying is essential to inform goals of care, appropriate treatment decisions, patient autonomy, and effective end-of-life care. Limited literature exists on predicting survival near the end of life for people with a hematological malignancy.

Objective: To identify the key clinical indicators that signal a person with a hematological malignancy is at high risk of deteriorating and dying.

Design, Setting, Participants: Eleven clinical indicators identified in a Delphi approach were tested via a retrospective case-control study. Each indicator was assessed for at each in-patient admission between living (n = 236) and deceased (n = 120) people with a hematological malignancy who were admitted to a large tertiary hospital between 1st July 2014 and 31st December 2015.

Results: Six clinical indicators were independently associated with mortality in the final three months of life: declining performance status (Odds Ratio [OR] 7.153, 95% Confidence Intervals [CI] 3.281-15.597, p = < 0.001); treatment limitations of the hematological malignancy (OR 7.855, 95% CI 3.528-17.489, p = < 0.001); relapse, refractory or persistent disease (OR 3.749, 95% CI 1.749-8.039, p = 0.001); presence of two or more comorbidities (OR 2.991, 95% CI 1.319-6.781, p = 0.009); invasive fungal infections (OR 4.887, 95% CI 1.197-19.949, p = 0.027); and persistent infections (OR 6.072, 95% CI 2.551-14.457, p = < 0.001).

Conclusions: This study has identified six clinical indicators that signal a person with a hematological malignancy is at high risk of deteriorating and dying and may benefit from an assessment of palliative needs and proactive planning, along-side appropriate treatment.

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/jpm.2018.0033
Publisher Site
http://dx.doi.org/10.1089/jpm.2018.0033DOI Listing
December 2018
31 Reads

Publication Analysis

Top Keywords

clinical indicators
16
hematological malignancy
12
risk deteriorating
12
people hematological
12
deteriorating dying
8
case-control study
8
study indicator
4
tested retrospective
4
delphi approach
4
approach tested
4
indicator assessed
4
retrospective case-control
4
in-patient admission
4
deceased n = 120
4
n = 120 people
4
malignancy admitted
4
n = 236 deceased
4
living n = 236
4
identified delphi
4
admission living
4

Similar Publications